Petrichor Team

Petrichor Capital Partners

Scion Life Sciences

Operations

Tadd Wessel is the founder and Managing Partner of Petrichor, a private investment firm focused on the healthcare sector. He is also a founder and Managing Partner of Scion Life Sciences, an affiliate of Petrichor. Tadd has more than 25 years of experience, primarily focused on investing and building companies in the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group focused on healthcare investments. Tadd began his career in the life sciences investment banking groups at Citigroup and Robertson Stephens.
Tadd has served on more than 30 boards most recently including Aurion Biotech, Cryoport (NASDAQ: CYRX), and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. He also serves on the Board of the International Centers for Precision Oncology (ICPO) whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally.
Tadd holds an AB in biology from Princeton University.

Tadd Headshot 01 Hayden

Tadd Wessel

Patrick Lally has over 15 years of healthcare investing experience. He joined Petrichor as a Partner at launch, and he is responsible for all aspects of the Fund’s investing activities including origination, diligence, and asset management. Patrick participates on the boards of Aurion Biotech, CorneaGen, ITM, Persivia, and Vero.
Prior to Petrichor, Patrick was an investor in the healthcare special situations and structured finance business at OrbiMed Advisors. Previously, he was focused on healthcare investments in the Drawbridge Special Opportunities Fund at Fortress Investment Group. Patrick began his career at Barclays Capital, where he worked in the capital markets and leveraged finance teams.
Patrick holds an M.B.A. from The Wharton School at the University of Pennsylvania and an A.B. in Molecular Biology from Princeton University.

PL 0082 Hayden

Patrick Lally

Michael Beecham has over a decade of healthcare investment and consulting experience. He joined Petrichor as a Partner at launch. Michael is responsible for investment in companies across the healthcare and life science ecosystem, from investment origination, management and strategic exit. Michael is currently on the boards of Ascend Gene and Cell Therapy, Fennec Pharmaceuticals (Nasdaq: FENC) and Leukocare AG. Previously, He participated on the boards of Cryoport (Nasdaq: CYRX) and Clearpoint (Nasdaq: CLPT), both successful, fully-realized exits.
Prior to Petrichor, Michael was at OrbiMed, working with Tadd and Patrick on the healthcare special situations and structured finance team. Additionally, he was an investment manager at Vatera Healthcare Partners, where he was responsible for sourcing and managing life science investments across preclinical through commercial stage, both public and private. Prior to that, Michael was at American Capital on the healthcare leveraged buyouts team (now part of Ares). He was also previously at Royalty Pharma (Nasdaq: RPRX) and Navigant Consulting (previously Easton Associates).
Michael has a B.S.E. in Bioengineering from the University of Pennsylvania.

MB 0233 Hayden

Michael Beecham

Hayden Fownes joined Petrichor at launch in 2018 and is a Vice President on the investment team. He supports all aspects of investment sourcing, execution, portfolio management, and fund operations for Petrichor Capital Partners. Hayden was previously in the Global Healthcare Investment Banking group at Bank of America Merrill Lynch, focused on M&amp;A and financings for clients across all healthcare and life sciences subsectors. He holds a B.S. in Finance from Wake Forest University.

HF 0030 Hayden

Hayden Fownes

Justin Lish is a Senior Associate at Petrichor. Prior to joining Petrichor, Justin worked at J.P. Morgan in their healthcare investment banking group, advising biotechnology and pharmaceutical clients on a range of strategic alternatives including M&amp;A and debt / equity financings. Justin graduated from the Roy and Diana Vagelos Program in Life Sciences &amp; Management at the University of Pennsylvania, where he earned both a B.A. in Biology and B.S. in Economics from the Wharton School with a concentration in Finance.

JL 0156 Hayden

Justin Lish

Dee van der Knaap is a Senior Associate at Petrichor. Dee was previously on the Business Development &amp; Strategy team at Entrada Therapeutics, where she helped the company grow from Series A to IPO. Dee started her career as an analyst at Bank of America Merrill Lynch on the #2 Institutional Investor ranked Life Science Tools &amp; Diagnostics Equity Research team. She holds a B.A. in Psychology from Wellesley College and an M.Sc. in Experimental &amp; Translational Therapeutics from the University of Oxford.

Dvd K 0089 Hayden

Dee van der Knaap

Lucy Burke is an Associate at Petrichor. Prior to joining Petrichor, Lucy worked as an associate at MTS Health Partners, a boutique investment bank focused exclusively on the healthcare industry, where she was involved in M&amp;A and equity financings across healthcare services and life sciences. She holds a B.A. in Psychology from Dartmouth College.

L Burke Headshot jpg

Lucy Burke

Sam is a founder and Managing Partner of Scion. He has more than 20 years of experience in the life sciences across roles as an investor, scientist and entrepreneur. From 2013 until October 2019, Sam was a Partner at Apple Tree Partners (ATP) where he focused on creating and building therapeutics companies. During his tenure at ATP, Sam contributed to the formation, financing and build-out of Syntimmune (acquired by Alexion Pharmaceuticals), Stoke Therapeutics (NASDAQ: STOK), Chinook Therapeutics (acquired by Novartis), Marengo Therapeutics and Ascidian Therapeutics and served as a member of each company’s Board of Directors. 
Before joining ATP in 2013, Sam was an immunologist at the University of Cambridge in the UK where his research focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to structured investments in development-stage therapeutics. Sam began his career as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements. In addition to his professional responsibilities, Sam serves as a Director of the Burke Neurological Institute, an independent neuroscience research institute affiliated with Weill Cornell Medicine.
Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.

SH 0125 Hayden

Samuel Hall, PhD

Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio (NASDAQ: TRML), where he has been serving since the company’s inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA) and assisted the team with other privately held therapeutics investments. Before joining Medicxi, he was a co-founder and founding board member of RayzeBio (NASDAQ: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY). 
From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking. 
Aaron received a B.S. in Finance and International Business from NYU Stern’s School of Business.

Aaron Kantoff Headshot 2024 01 22 174126 mkgm 2024 01 31 232704 afkv

Aaron Kantoff

Andreas is a Partner at Scion. He is a 20+-year industry veteran, with protein engineering and structural biology expertise at large and small pharma. Before joining the firm, he was the founder and CSO of Marengo Therapeutics, a developer of transformational protein therapeutics targeting TCRvβ chains for cancer. Previously, he led New Technologies for Biologics at Novartis, heading a research group responsible for the discovery and development of complex biologics, cell, gene and nucleic acid therapies.
In addition to discovering many innovative protein therapeutics, he was the principal inventor of core technologies that established Novartis’ adoptive T-cell therapy portfolio that ultimately led to the first FDA-approved CAR-T product, Kymriah. At Abbott Laboratories, he was instrumental in solving the crystal structure of Humira bound to its target TNF. Andreas is an inventor on &gt;450 patents and patent applications.
Andreas received his Ph.D. in Germany at the University of Bayreuth followed by post-doctoral education in biochemistry and structural biology at the University of Illinois, Birkbeck College London and UT Southwestern Medical Center, Dallas TX. He received the prestigious Novartis VIVA award for his many contributions to the life sciences.

AL 0014 Hayden

Andreas Loew, PhD

Andy is a Venture Partner at Scion Life Sciences. For over two decades, he headed Nature Biotechnology, one of the biopharmaceutical industry’s leading journals in translational research. In 2015, he was cited by Scientific American as one of the 100 most influential people in biotechnology. As well as writing over 500 articles and editorials, he has hosted scientific conferences with leading academic institutions around the world. He was also a co-founder of the Nature SciCafe 10-year event series of faculty networking events with top venture and industry stakeholders in Boston, New York, San Francisco, San Diego, Houston, London and Singapore. 
Andy obtained his Ph.D. in molecular biology and microbiology at King’s College London, where he also carried out his postdoctoral research. He was an adjunct professor at the University of Miami and a recipient of the Helen White Prize.

AM 0205 Hayden

Andy Marshall, PhD

William is an Associate at Scion. Prior to joining the Scion investment team in a full-time capacity William worked with the firm as a member of the inaugural cohort of Scion Fellows. 
William holds an M.D. from the Keck School of Medicine of USC and a Ph.D. from the California Institute of Technology, where he worked in the laboratory of James R. Heath to develop immunotherapy technologies for oncology and COVID-19. He received his A.B. in Chemistry from Princeton University.

WC Scion Headshot

Wiliam Chour, MD, PhD

Sam is an Associate at Scion. Prior to joining the firm in April 2023, Sam was a postdoctoral fellow in the laboratory of David Baker within the Institute of Protein Design at the University of Washington. Sam holds a B.A. in Chemistry and Mathematics from Amherst College, and a Ph.D. in Biological Chemistry from MIT, where he was an NSF Graduate Research Fellow.

SJH Scion Headshot

Samuel Hendel, PhD

David Katona is the Head of Business Development and Investor Relations at Petrichor. Dave has 20+ years of capital formation experience and leads all marketing, development, and fundraising initiatives for Petrichor and affiliate firm Scion. Prior to joining Petrichor in March 2021, Dave was part of the Capital Introductions Group at Jefferies Group, where he managed institutional relationships, spanning endowments, foundations, family offices, and others. He also ran the group’s uncorrelated/niche co-investment outreach programs. Previously, Dave was a Partner at Abundance Partners. He holds a Bachelors of Arts degree in Political Science with a concentration in Economics from Bates College.

David Katona Headshot Updated

David Katona

Eidul (Eddie) Hossein has over 20 years of experience in financial, operational, and administrative areas in the alternative investment industry. At Petrichor Eddie is responsible for finance administration, including accounting, reporting, budgeting, treasury management, and various compliance activities. Prior to joining Petrichor, Eddie was the Controller Colbeck Capital Management and DiMaio Ahmad Capital, alternative investment management firms specializing in credit products. He also held various positions at PricewaterhouseCoopers and JPMorgan Chase. He holds a dual Bachelor of Business Administration degree in Accounting Information Systems and Economics from the Queens College of the City University of New York.

We are a team of scientific, medical, financial, technological, and operational leaders built to serve our partners

Our deep understanding of subsector-specific scientific, regulatory, and commercial dynamics underpins everything we do.